To gain insights into the role of CDKs in breast cancer, we first explored the association between the expression of different CDKs and patient outcomes in the four described breast cancer molecular subtypes (basal-like, HER2+, Luminal A, and Luminal B with Status HER2+). This evidence concerns the gene ERBB2 and breast carcinoma.